Citation

Cristina P, Victoria A. Therapeutics, Pharmacology and Clinical Toxicology 2012; 16(2): 77-84.

Copyright

(Copyright © 2012)

DOI

unavailable

PMID

unavailable

Abstract

Pegylated interferon and ribavirin are mandatory in the treatment of HCV hepatitis. An earlyrecognition of side effects related to the antiviral therapy can prevent the discontinuation of treatment andcan improve the eradication of HCV infection. Hematologic side effects related to pegylated interferonand ribavirin therapy are the most studied; on the other hand it is difficult to make a correlation betweena rarely reported side effect and the medication. That's why it is important to report and to recognizeall these side effects in order to avoid life-threatening. This review analyses non-hematologic side effectscorrelated with antiviral therapy for HCV hepatitis. © Copyright reserved 2012.

Language: en

Keywords

human; suicide; insomnia; depression; anxiety; scoring system; major depression; disease severity; pathogenesis; article; autoimmune disease; sudden death; cardiotoxicity; cardiomyopathy; rheumatoid arthritis; interferon; heart muscle conduction disturbance; alpha interferon; drug withdrawal; hepatitis C; irritability; asthma; drug megadose; congestive heart failure; side effect; heart arrhythmia; anemia; hyperthyroidism; ribavirin; thyroiditis; peripheral neuropathy; plasmapheresis; insulin dependent diabetes mellitus; drug monitoring; hypothyroidism; dyspnea; coughing; melanoma; peginterferon; drug dose reduction; mental concentration; polyneuropathy; kidney carcinoma; prednisolone; acute coronary syndrome; Pegylated interferon; sensory neuropathy; interstitial pneumonia; retinopathy; autonomic neuropathy; immunoglobulin; pleura effusion; chronic myeloid leukemia; respiratory distress syndrome; pericarditis; antiviral therapy; thyroid peroxidase antibody; chronic bronchitis; classification algorithm; demyelinating neuropathy; dry cough; HCV hepatitis; Side effect; thyroid antibody; Vogt Koyanagi syndrome